



## **Verve Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference**

**January 6, 2021 4:00 PM EST**

CAMBRIDGE, Mass. — January 6, 2021 [Verve Therapeutics](#), a biotech company pioneering gene editing medicines to treat cardiovascular disease, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will present a company overview during the 39<sup>th</sup> Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 9:15 a.m. ET. Dr. Kathiresan's presentation will include an overview of Verve's strategy to create once-and-done gene editing medicines for coronary heart disease and an update on the company's preclinical progress.

Gene editing is a promising new treatment approach for coronary heart disease, the leading cause of death worldwide. Genetic studies have revealed gene variants that naturally turn off a disease-causing gene in the liver and dramatically lower some individuals' lifetime risk of coronary heart disease. These individuals have low levels of LDL cholesterol or triglycerides lifelong, are protected against heart attack, and are otherwise healthy. Verve is developing gene editing medicines to safely turn off a target gene in the liver and mimic naturally-protective variants to permanently lower LDL cholesterol and triglyceride levels and thereby treat coronary heart disease.

### **About Verve Therapeutics**

Verve Therapeutics is a biotechnology company created with a singular focus: to protect the world from heart disease. The company brings together human genetics analysis and gene editing – two of the biggest breakthroughs in 21st century biomedicine – to develop transformative therapies for coronary heart disease. Verve is developing medicines, administered once in life, to safely edit the genome of adults and mimic naturally occurring gene variants to permanently lower LDL cholesterol and triglyceride levels and thereby treat coronary heart disease. Founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, Verve is backed by a top-tier syndicate of investors, including GV (formerly Google Ventures), ARCH Venture Partners, F-Prime Capital, Biomax Capital, Wellington Management, Casdin Capital, and Partners Innovation Fund. Verve is headquartered in Cambridge, Massachusetts. For more information, visit [www.VerveTx.com](http://www.VerveTx.com).

### **Media Contact**

Gina Nugent, 617-460-3579  
Ten Bridge Communications  
[gina@tenbridgecommunications.com](mailto:gina@tenbridgecommunications.com)

### **Investor Contact**

Monique Allaire  
THRUST Strategic Communications  
[monique@thrustsc.com](mailto:monique@thrustsc.com)